Xuanzhubio-b
Status: Publicly traded
Direct answer
Xuanzhubio-b is publicly traded on HKSE under the ticker 2575.HK.
Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Core- KBP-3571, developed for treating duodenal ulcers; XZP-3287, a CDK4/6 inhibitor aimed at advanced HR+/HER2 breast cancer; and XZP-3621, intended as a first-line...
Can you invest in Xuanzhubio-b?
Yes. Xuanzhubio-b is publicly traded on HKSE under the ticker 2575.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Xuanzhubio-b
Detailed equity research is provided by MarketSnap.